What Happened?
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
The president's tone and the suggestion of canceling a meeting with President Xi caused a rapid sell-off in the market. The trade dispute flared up after China imposed export controls on rare earth minerals, which are critical components for high-tech manufacturing. The escalation of the trade war raises concerns about supply chain disruptions and increased costs for technology companies, which are heavily reliant on global trade, leading to a broad sell-off in the sector.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Genomics & Sequencing company 10x Genomics (NASDAQ: TXG) fell 3.5%. Is now the time to buy 10x Genomics? Access our full analysis report here, it’s free for active Edge members.
- Therapeutics company BioMarin Pharmaceutical (NASDAQ: BMRN) fell 3.3%. Is now the time to buy BioMarin Pharmaceutical? Access our full analysis report here, it’s free for active Edge members.
- Specialized Medical & Nursing Services company AMN Healthcare Services (NYSE: AMN) fell 3.7%. Is now the time to buy AMN Healthcare Services? Access our full analysis report here, it’s free for active Edge members.
- Genomics & Sequencing company Illumina (NASDAQ: ILMN) fell 3.4%. Is now the time to buy Illumina? Access our full analysis report here, it’s free for active Edge members.
- Therapeutics company Moderna (NASDAQ: MRNA) fell 3.5%. Is now the time to buy Moderna? Access our full analysis report here, it’s free for active Edge members.
Zooming In On AMN Healthcare Services (AMN)
AMN Healthcare Services’s shares are very volatile and have had 29 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 10 days ago when the stock gained 4% on the news that reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
The Trump administration is advancing its “Most Favored Nation” initiative, which aims to lower prescription drug costs for Americans. This policy would tie the prices of medications in the U.S. to the lowest costs paid by other wealthy nations. As part of this push, Pfizer has reportedly entered into an agreement to voluntarily sell its medications through Medicaid at these reduced prices. The move comes as the administration intensifies pressure on drugmakers to make prices more affordable. While pricing controls can often be a headwind, the market's positive reaction suggests that investors may see this voluntary agreement as a way to resolve regulatory uncertainty, providing a clearer path forward for the industry.
AMN Healthcare Services is down 25.9% since the beginning of the year, and at $18.18 per share, it is trading 57.1% below its 52-week high of $42.42 from October 2024. Investors who bought $1,000 worth of AMN Healthcare Services’s shares 5 years ago would now be looking at an investment worth $277.13.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
